Patents Assigned to Amgen
  • N-terminally chemically modified protein compositions and methods
    Publication number: 20060233746
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Application
    Filed: April 26, 2006
    Publication date: October 19, 2006
    Applicant: AMGEN INC.
    Inventors: Olaf Kinstler, Nancy Gabriel, Christine Farrar, Randolph DePrince
  • Method for selectively blocking hemoglobin RNA amplification
    Publication number: 20060234277
    Abstract: This invention provides oligonucleotides, compositions, kits, and methods for specifically blocking amplification of hemoglobin mRNA in a sample of RNA. The oligonucleotides and methods are particularly advantageous for analyzing samples of RNA extracted from whole blood samples.
    Type: Application
    Filed: March 31, 2006
    Publication date: October 19, 2006
    Applicant: Amgen Inc.
    Inventors: Chris Russell, Keith Kerkof, Martin Timour
  • Methods of modulating appetite using agouti-related transcript polypeptides
    Patent number: 7122520
    Abstract: Disclosed is a novel gene termed ART which is expressed primarily in selected regions of the brain, as well as adrenal and lung tissues. Polypeptides encoded by ART are also disclosed, as are methods for preparing ART DNA and amino acid sequences.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: October 17, 2006
    Assignee: Amgen Inc.
    Inventor: Kevin Lee Stark
  • 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
    Patent number: 7119111
    Abstract: Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: May 27, 2003
    Date of Patent: October 10, 2006
    Assignee: Amgen, Inc.
    Inventors: Qi Huang, Matthew Kaller, Thomas Nguyen, Mark H. Norman, Robert Rzasa, Hui-Ling Wang, Wenge Zhong
  • Method for controlling metallophosphate precipitation in high cell density fermentations
    Patent number: 7118884
    Abstract: The invention relates to the use of a phosphate glass as a phosphorus source in the media of high cell density bacterial fermentation processes in order to reduce metallophosphate precipitation reactions. The methods of the invention demonstrate a practical method for controlling levels of metallophosphate precipitation in both the nutrient media and the fermentor which also result in increased cell densities and are useful in a variety of high cell density bacterial fermentation processes.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: October 10, 2006
    Assignee: Amgen Inc.
    Inventors: Craig Eric Curless, Jeffrey Burke Baclaski
  • Methods for detecting NTR3 nucleic acids by hybridization
    Patent number: 7118863
    Abstract: The present invention provides a purified polynucleotide encoding a novel receptor, designated NTR3, which belongs to the TNF receptor gene superfamily; to purified NTR3 polypeptide molecules; to antibodies that bind NTR3; to materials comprising such molecules; and to methods of using such molecules.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: October 10, 2006
    Assignee: Amgen, Inc.
    Inventor: Hailing Hsu
  • G protein-coupled receptors
    Publication number: 20060223109
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of the receptors.
    Type: Application
    Filed: June 14, 2006
    Publication date: October 5, 2006
    Applicant: Amgen, Inc.
    Inventors: Hui Tian, Jiagang Zhao, Jin-Long Chen, Gene Cutler
  • Substituted piperazinyl amides and methods of use
    Patent number: 7115607
    Abstract: Selected substituted piperazine compounds of Formula I are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: October 3, 2006
    Assignee: Amgen Inc.
    Inventors: Christopher H. Fotsch, Premilla Arasasingham, Yunxin Bo, Ning Chen, Martin H. Goldberg, Nianhe Han, Feng-Yin Hsieh, Michael G. Kelly, Qingyian Liu, Mark H. Norman, Duncan M. Smith, Markian Stec, Nuria Tamayo, Ning Xi, Shimin Xu
  • Amino-substituted pyrimidinyl derivatives and methods of use
    Patent number: 7115617
    Abstract: The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: October 3, 2006
    Assignee: Amgen Inc.
    Inventors: John L. Buchanan, Stuart Chaffee, Jean-Christophe Harmange, Perry M. Novak, Xiaotian Zhu
  • Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
    Patent number: 7115368
    Abstract: The present invention provides methods, reagents, and kits for diagnosing and treating cancer in a mammal, e.g., a human. This invention is based upon the discovery that Pellino 1 or 2 is overexpressed and/or amplified in cancer. Methods to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and to treat cancer, by inhibiting the expression and/or activity of Pellino 1 or 2 in a cancer cell are included.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: October 3, 2006
    Assignee: Amgen SF, LLC
    Inventors: Scott Powers, David Mu, Phil Xiang, Yue Peng
  • Combinations for the treatment of cancer
    Publication number: 20060216288
    Abstract: This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.
    Type: Application
    Filed: March 21, 2006
    Publication date: September 28, 2006
    Applicant: Amgen Inc
    Inventor: David Chang
  • Heterocyclic arylsulfonamidobenzylic compounds
    Patent number: 7112606
    Abstract: Heterocyclic arylsulfonamidobenzylic compounds are provided which are useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: September 26, 2006
    Assignee: Amgen Inc.
    Inventors: Xian Yun Jiao, Frank Kayser, David J. Kopecky, Sharon McKendry, Derek E. Piper, Andrew K. Shiau
  • OB fusion protein compositions and methods
    Patent number: 7112659
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: September 26, 2006
    Assignee: Amgen, Inc.
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pelleymounter, Christopher Francis Toombs
  • Detection of compounds that affect therapeutic activity
    Publication number: 20060211022
    Abstract: The present invention relates to methods of detecting compounds that affect the activity of a therapeutic substance or composition administered to a subject, and to reagents for use in such methods.
    Type: Application
    Filed: February 23, 2006
    Publication date: September 21, 2006
    Applicant: Amgen Inc.
    Inventors: Shuqian Jing, Francesca Civoli, Shalini Gupta, Daniel Halperin, Jason Pennucci, Steven Swanson, Yan Yu
  • Substituted amine derivatives and methods of use
    Patent number: 7105682
    Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: September 12, 2006
    Assignee: Amgen Inc.
    Inventors: Guoqing Chen, Jeffrey Adams, Jean Bemis, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Qi Huang, Joseph L. Kim, Xiaohu Ouyang, Vinod F. Patel, Leon M. Smith, Andrew Tasker, Ning Xi, Shimin Xu, Chester Chenguang Yuan, Michael Croghan, Tae-Seong Kim
  • Cell-based drug screens for regulators of gene expression
    Patent number: 7105313
    Abstract: The invention provides methods and compositions for screening for pharmacological agents which regulate gene expression in mammals. An exemplary assay involves (a) contacting a mammalian cell comprising a knock-in mutant of a targeted native allele encoding a reporter of gene expression, wherein the expression of the reporter is under the control of the gene expression regulatory sequences of the native allele, with a candidate agent under conditions whereby but for the presence of the agent, the reporter is expressed at a first expression level; and, (b) measuring the expression of the reporter to obtain a second expression level, wherein a difference between the first and second expression levels indicates that the candidate agent modulates gene expression.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: September 12, 2006
    Assignee: Amgen Inc.
    Inventors: Bei Shan, R. Marc Learned, M. Catherine Amaral, Steven L. McKnight, Fabienne C. de la Brousse, Jin-Long Chen
  • Substituted benzofused heterocycles
    Publication number: 20060199796
    Abstract: The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.
    Type: Application
    Filed: August 12, 2005
    Publication date: September 7, 2006
    Applicant: Amgen Inc.
    Inventors: Xi Chen, Xiaoqi Chen, Richard Connors, Kang Dai, Ying Fu, Juan Jaen, Yong-Jae Kim, Leping Li, Mike Lizarzaburu, Jeffrey Mihalic, Stephen Shuttleworth
  • Phthalazine, aza- and diaza-phthalazine compounds and methods of use
    Publication number: 20060199817
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: March 2, 2006
    Publication date: September 7, 2006
    Applicant: Amgen Inc.
    Inventors: Andrew Tasker, Dawei Zhang, Guo-Qiang Cao, Partha Chakrabarti, James Falsey, Bradley Herberich, Randall Hungate, Liping Pettus, Anthony Reed, Robert Rzasa, Kelvin Sham, Maya Thaman, Shimin Xu
  • Substituted arylamine derivatives and methods of use
    Patent number: 7101868
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: September 5, 2006
    Assignee: Amgen Inc.
    Inventors: Daniel Elbaum, Benny C. Askew, Jr., Shon Booker, Julie Germain, Gregory J. Habgood, Michael Handley, Tae-Seong Kim, Aiwen Li, Nobuko Nishimura, Vinod F. Patel, Chester Chenguang Yuan, Joseph L. Kim, Guolin Cai, Guoqing Chen, Michael Croghan, Lucian V. Di Pietro, Celia Dominguez, Qi Huang, Leon M. Smith, II, Andrew Tasker, Ning Xi, Shimin Xu
  • Syringe tool
    Patent number: D530009
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: October 10, 2006
    Assignee: Amgen Inc.
    Inventors: Scott D. Lyman, B. Cameron Smith